Table 5 Drugs intake among COVID-19 patients with and without CMV or EBV coinfection (n = 110)
From: Epstein–Barr virus and cytomegalovirus coinfection in Egyptian COVID-19 patients
Either CMV or EBV | P | ||
|---|---|---|---|
Negative | Positive | ||
N (%) | N (%) | ||
Steroids | |||
Not taken | 36 (36) | 3 (30) | 1.000 |
Taken | 64 (64) | 7 (70) | |
Anti-inflammatory drugs | |||
Not taken | 11 (11.2) | 3 (33.3) | .094 |
Taken | 87 (88.8) | 6 (66.7) | |
Anti-viral drugs | |||
Not taken | 11 (11) | 1 (10) | 1.000 |
Taken | 89 (89) | 9 (90) | |
Anti-coagulant drugs | |||
Not taken | 13 (13) | 2 (20) | .624 |
Taken | 87 (87) | 8 (80) | |
Vitamins | |||
Not taken | 10 (10) | 4 (40) | .023* |
Taken | 90 (90) | 6 (60) | |
Antipyretic and analgesics | |||
Not taken | 9 (9.2) | 3 (33.3) | .062 |
Taken | 89 (90.8) | 6 (66.7) | |
Antibiotic | |||
Not taken | 3 (3) | 3 (30) | .010* |
Taken | 97 (97) | 7 (70) | |